Tailwinds' Take: it looks like Dr. Day is being given the keys to the house as the founder steps aside. The new CEO's background and resume are impeccable and it's great to see someone of his experience take over...
Tailwinds' Take: This is excellent progress. If it translates into human data, a decent probability, it could be huge. Once they get properly funded and on Nasdaq, Bioasis should start to attract some real investor attention. We entered early...
On Friday, my favorite little boom or bust biotech, Bioasis, reported their results. There is very little to learn from looking at the numbers; this is a tiny, pre-revenue company. However, in the MD&A section of the filing was...
Tailwinds' Take: a long anticipated licensing deal is likely a major sigh of relief for shares of BIOAF. While small in size, a $1M upfront fee signals that they have made substantial progress. Which may also be signaling that...
VANCOUVER, British Columbia & GUILFORD, Conn.–(Business Wire)– Bioasis Technologies, Inc . (OTCQB:BIOAF; TSX.V:BTI), a biopharmaceutical company with a proprietary blood-brain barrier platform delivery technology focused on development of therapeutics for the treatment of brain cancers and neurodegenerative diseases, today announced a key...
Tailwinds' Take: The Company needed this cash infusion rather desperately. I believe that management participated in the transaction. The technology is solid, but they need to develop a long-term plan to fund Bioasis. GUILFORD, Conn.–(Business Wire)– Bioasis Technologies, Inc. (“Bioasis” or the...
Those who know me well are well aware that Wednesdays are my favorite night of the week. That's the night I go out mountain biking with The Gestalt Haus Gang, ending up at a similarly-named (mountain) biker bar tipping...
Tailwinds' Take: Positive in that the timeline for development appears to be unchanged post the meeting, so that implies there were no significant issues from the FDA's side. How they fund this going forward remains a mystery to me....
VANCOUVER, British Columbia & GUILFORD, Conn.–(Business Wire)– Bioasis TECHNOLOGIES, INC . (TSX.V:BTI; OTCQB:BIOAF), a biopharmaceutical company with a proprietary blood-brain barrier platform technology focused on development of therapeutics for the treatment of brain cancers and neurodegenerative diseases, today announced that Dr. Deborah...
Tailwinds' Take: Obviously, this cash was needed and will not suffice them for long. We would like to see just how much director and management participation took place in this round. The next catalyst is an FDA meeting in...
DFC Advisory Services LLC (dba Tailwinds Research) is a registered investment adviser. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Past performance is not indicative of future performance.